Omalizumab is administered in bronchial asthma by which route?
**Core Concept**
Omalizumab is a recombinant humanized monoclonal antibody that targets IgE, thereby reducing its levels and modulating the allergic response. It is used in the management of severe asthma that is inadequately controlled with inhaled corticosteroids.
**Why the Correct Answer is Right**
Omalizumab is administered subcutaneously (SC) every 2-4 weeks, depending on the patient's IgE levels and body weight. This SC route allows for slow and sustained release of the drug, providing therapeutic effects on the allergic response. The SC injection is typically given in the abdominal or thigh area, minimizing discomfort and improving patient compliance.
**Why Each Wrong Option is Incorrect**
**Option A:** Intravenous (IV) administration would not be practical for long-term management of asthma, as it would require frequent hospital visits and may not provide sustained therapeutic effects.
**Option B:** Oral administration would result in rapid metabolism and inactivation of omalizumab, making it ineffective for treating chronic conditions like asthma.
**Option C:** Intramuscular (IM) administration may not provide consistent therapeutic effects due to variations in muscle absorption and distribution of the drug.
**Clinical Pearl / High-Yield Fact**
Omalizumab is a biologic agent that requires careful monitoring of IgE levels and dosing adjustments to minimize the risk of anaphylaxis.
**Correct Answer:** C. Subcutaneous.